VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives

Reuters03-18 20:17

VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives

Volition reported an updated manuscript describing a two-step method that generated sequencing datasets with more than 99% purity for circulating tumor-derived DNA from blood samples of cancer patients. The manuscript includes proof-of-concept and early blinded validation results that reported 49 of 49 cancers detected in one cohort and 13 of 14 later-stage cancers detected in a second blinded cohort. The company said it is working on an additional validation cohort focused on early-stage cancers, with results expected in the future. Volition also cited a total addressable market estimate of about USD 23 billion for multi-cancer early detection and more than USD 13 billion for minimal residual disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180817PR_NEWS_USPR_____LN13222) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620925344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620925344","market":"us","top_or_hot":-1,"title":"VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Volition reported an updated manuscript describing a two-step method that generated sequencing datasets with more than 99% purity for circulating tumor-derived DNA from blood samples of cancer patients. The manuscript includes proof-of-concept and early blinded validation results that reported 49 of 49 cancers detected in one cohort and 13 of 14 later-stage cancers detected in a second blinded cohort. The company said it is working on an additional validation cohort focused on early-stage cancers, with results expected in the future. Volition also cited a total addressable market estimate of about USD 23 billion for multi-cancer early detection and more than USD 13 billion for minimal residual disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180817PR_NEWS_USPR_____LN13222) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 20:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Volition reported an updated manuscript describing a two-step method that generated sequencing datasets with more than 99% purity for circulating tumor-derived DNA from blood samples of cancer patients. The manuscript includes proof-of-concept and early blinded validation results that reported 49 of 49 cancers detected in one cohort and 13 of 14 later-stage cancers detected in a second blinded cohort. The company said it is working on an additional validation cohort focused on early-stage cancers, with results expected in the future. Volition also cited a total addressable market estimate of about USD 23 billion for multi-cancer early detection and more than USD 13 billion for minimal residual disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180817PR_NEWS_USPR_____LN13222) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2mBks6:1","article_id":"2620925344","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620925344","pubTimestamp":1773836236,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Volition reported an updated manuscript describing a two-step method that generated sequencing datasets with more than 99% purity for circulating tumor-derived DNA from blood samples of cancer patients. The manuscript includes proof-of-concept and early blinded validation results that reported 49 of 49 cancers detected in one cohort and 13 of 14 later-stage cancers detected in a second blinded cohort. The company said it is working on an additional validation cohort focused on early-stage cancers, with results expected in the future. Volition also cited a total addressable market estimate of about USD 23 billion for multi-cancer early detection and more than USD 13 billion for minimal residual disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","VNRX":"VolitionRX Ltd"},"translate_title":"VolitionRx报告临床验证结果显示检测到49/49癌症，无假阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNRX":0.9},"content_text":"VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives\n    \n\n        Volition reported an updated manuscript describing a two-step method that generated sequencing datasets with more than 99% purity for circulating tumor-derived DNA from blood samples of cancer patients. The manuscript includes proof-of-concept and early blinded validation results that reported 49 of 49 cancers detected in one cohort and 13 of 14 later-stage cancers detected in a second blinded cohort. The company said it is working on an additional validation cohort focused on early-stage cancers, with results expected in the future. Volition also cited a total addressable market estimate of about USD 23 billion for multi-cancer early detection and more than USD 13 billion for minimal residual disease.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180817PR_NEWS_USPR_____LN13222) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620925344","isCrawlerRequest":true}